BriaCell Therapeutics Corp Warrants (24/02/2025) BCTXW 深 滬
等待開盤 08-22 09:30:00 美东时间
0.0206
-0.005
-18.58%
華盛通- 最 高0.0217
- 今 開0.0217
- 成交量 500股
- 最 低 0.0206
- 昨 收 0.0253
- 總市值 15.53万
- 52周最高 0.70
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0113
- 委 比 16.67%
- 總股本 753.67万
- 歷史最高 7.04
- 量 比 0.01
- 振 幅 4.35%
- 歷史最低 0.0113
- 每 手 1
- 風險率 0.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BriaCell Announces 1-for-10 Share Consolidation To Maintain Nasdaq Listing, Effective August 25, 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that
今天 00:02
BriaCell Joins MSK's 2025 Therapeutics Accelerator to Fast-Track Cancer Immunotherapy
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
08-13 19:36
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. announced its acceptance into Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator program to accelerate the clinical development of its Bria-OTS+ immunotherapy for multiple cancers, including breast and prostate cancer. MSK’s resources will support regulatory and manufacturing efforts, with both parties expressing confidence in the therapy’s potential to advance cancer care.
08-13 11:30
BriaCell Unveils TILsRx Platform Aiming To Supercharge Immune Response Against Hard-To-Treat Cancers
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))), (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary,
07-29 19:34
BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics Corp. has completed a best-efforts public offering of 12 million units, raising $15 million gross proceeds. Each unit includes one common share or a pre-funded warrant and one warrant. The pre-funded warrants are exercisable at $0.001, while the warrants are exercisable at $1.50 per share for five years. The company intends to use the net proceeds for working capital, general corporate purposes, and advancing business object...
07-16 20:05
BriaCell Therapeutics Reports Updated Results From Ongoing Phase 2 Study Of Bria-IMT In Combination With Check Point Inhibitor In Patients With Advanced Metastatic Breast Cancer
Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment"Eye bulging" metastatic breast cancer patient had failed 8 prior regimens, including
07-10 19:34
BriaCell Adds Two Key Large Cancer Centers To Ongoing Pivotal Phase 3 Clinical Study; Expects Completing Patient Enrollment In Late 2025 Or Early 2026 And May Report Top Line Data As Early As H1-2026
Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell's pivotal Phase 3 studyBriaCell's Phase 3 study currently has 58 active clinical
07-02 19:37
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
BriaCell Therapeutics has expanded its pivotal Phase 3 clinical study by adding 30 satellite locations through Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven. The study now includes 58 active sites across 15 states. BriaCell aims to complete patient enrollment by late 2025 or early 2026, with potential top-line data available as early as H1-2026. The Phase 3 trial evaluates Bria-IMT plus immune checkpoint inhibitor in adv...
07-02 11:30
BriaCell Highlights Breast Cancer Trial Data at 2025 ASCO Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical
06-02 19:34
BriaCell Therapeutics To Highlight Survival And Clinical Benefit Data In Three Clinical Poster Presentations And One Publish-Only Abstract At 2025 ASCO Annual Meeting
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuationsSuccessful completion of the pivotal
05-23 19:33
